MELVILLE, N.Y., Feb. 13, 2026 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Firm”) (NASDAQ:BRTX), a late stage scientific regenerative drugs innovator targeted on stem cell-based therapies and merchandise, at present introduced the closing of its beforehand introduced public providing of 14,285,715 shares of widespread inventory (or pre-funded warrants in lieu thereof) and warrants to buy as much as 14,285,715 shares of widespread inventory, at a mixed public providing worth of $0.35 per share (or pre-funded warrant in lieu thereof) and accompanying warrants. The warrants have an train worth of $0.35 per share, are instantly exercisable and can expire 5 years from the date of issuance.
Rodman & Renshaw LLC acted because the unique placement agent for the providing.
The gross proceeds to the Firm from the providing have been roughly $5.0 million, earlier than deducting the position agent’s charges and different providing bills payable by the Firm. The Firm intends to make use of the web proceeds from this providing for its scientific trials with respect to BRTX-100, pre-clinical analysis and growth with respect to its ThermoStem Program, the event of its business biocosmeceuticals platform and for normal company functions and dealing capital.
A registration assertion on Type S-1, as amended (File No. 333-293322), regarding the providing was declared efficient by the Securities and Alternate Fee (the “SEC”) on February 11, 2026. The providing was made solely by way of a prospectus forming a part of the efficient registration assertion regarding the providing. A ultimate prospectus regarding the providing has been filed with the SEC. Digital copies of the ultimate prospectus could also be obtained on the SEC’s web site at http://www.sec.gov and might also be obtained by contacting Rodman & Renshaw LLC at 600 Lexington Ave, Flooring 32, New York, NY 10022, by telephone at (212) 540-4414 or e-mail at data@rodm.com.
This press launch doesn’t represent a proposal to promote or the solicitation of a proposal to purchase any of the securities described herein, nor shall there be any sale of those securities in any state or different jurisdiction wherein such a proposal, solicitation or sale could be illegal previous to registration or qualification below the securities legal guidelines of any such state or different jurisdiction.
About BioRestorative Therapies, Inc.
BioRestorative (www.biorestorative.com) develops therapeutic merchandise utilizing cell and tissue protocols, primarily involving grownup stem cells. As described under, our two core scientific growth packages relate to the therapy of disc/backbone illness and metabolic issues, and we additionally function a business BioCosmeceutical platform:
• Disc/Backbone Program (brtxDISC™): Our lead cell remedy candidate, BRTX-100, is a product formulated from autologous (or an individual’s personal) cultured mesenchymal stem cells collected from the affected person’s bone marrow. We intend that the product will probably be used for the non-surgical therapy of painful lumbosacral disc issues or as a complementary therapeutic to a surgical process. The BRTX-100 manufacturing course of makes use of proprietary know-how and entails accumulating a affected person’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient process, BRTX-100 is to be injected by a doctor into the affected person’s broken disc. The therapy is meant for sufferers whose ache has not been alleviated by non-invasive procedures and who doubtlessly face the prospect of surgical procedure. Now we have commenced a Section 2 scientific trial utilizing BRTX-100 to deal with continual decrease again ache arising from degenerative disc illness. Now we have additionally obtained U.S. Meals and Drug Administration (“FDA”) Investigational New Drug (“IND”) clearance to guage BRTX-100 within the therapy of continual cervical discogenic ache.
• Metabolic Program (ThermoStem®): We’re creating cell-based remedy candidates to focus on weight problems and metabolic issues utilizing brown adipose (fats) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), in addition to exosomes secreted by BADSC. BAT is meant to imitate naturally occurring brown adipose depots that regulate metabolic homeostasis in people. Preliminary preclinical analysis signifies that elevated quantities of brown fats in animals could also be liable for extra caloric burning in addition to decreased glucose and lipid ranges. Researchers have discovered that folks with greater ranges of brown fats might have a decreased danger for weight problems and diabetes. BADSC secreted exosomes might also impression weight reduction.
• BioCosmeceuticals: We function a business BioCosmeceutical platform. Our present business product, formulated and manufactured utilizing our cGMP ISO-7 licensed clear room, is a cell-based secretome containing exosomes, proteins and development components. This proprietary biologic serum has been particularly engineered by us to cut back the looks of nice strains and wrinkles and produce forth different areas of beauty effectiveness. Shifting ahead, we additionally intend to discover the potential of increasing our business providing to incorporate a broader household of cell-based biologic aesthetic merchandise and therapeutics by way of IND-enabling research, with the intention of pioneering FDA approvals within the rising BioCosmeceuticals area.
Ahead-Wanting Statements
This press launch comprises “forward-looking statements” inside the that means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Alternate Act of 1934, as amended, and such forward-looking statements are made pursuant to the protected harbor provisions of the Personal Securities Litigation Reform Act of 1995. You might be cautioned that such statements are topic to a large number of dangers and uncertainties that would trigger future circumstances, occasions or outcomes to vary materially from these projected within the forward-looking statements because of numerous components and different dangers, together with, with out limitation, the Firm’s meant use of proceeds from the providing, and people set forth within the Firm’s newest Type 10-Ok, filed with the Securities and Alternate Fee and subsequent filings with the SEC. You must take into account these components in evaluating the forward-looking statements included herein, and never place undue reliance on such statements. The forward-looking statements on this launch are made as of the date hereof and the Firm undertakes no obligation to replace such statements.
CONTACT:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
E-mail: skilmer@biorestorative.com
Source link
#BioRestorative #Publicizes #Closing #Million #Public #Providing
